Current clinical practice guidelines for the early detection of prostate cancer recommend for clinical decision making a personalised prostate-specific antigen (PSA)-based management to improve the risk–benefit ratio of the screening strategy. The gene discussed is KLK3; the disease is prostate carcinoma.